Skip to content

The Preparation and Clinical Trial of Tangluoning Plaster on Diabetic Peripheral Neuropathy

The Clinical Trial of Tangluoning Plaster on Diabetic Peripheral Neuropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003893
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Interventions

Sponsors

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria for diabetic peripheral neuropathy; and Xiaoke Bi syndrome. (2) Between the ages of 18 and 75 (including 18 and 75); No gender restriction. (3) HBA1c <= 9%, with fasting blood glucose <= 10mmol/L, 2h postprandial blood glucose <= 16mmol/L. (4) Patients with sufficient education and understanding ability. (5) Patients who agree to participate in all clinical interviews, examinations and test procedures required by this protocol and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with diseases such as mania, bipolar disorder and cognitive dysfunction. (2) Patients who are unstable with serious disease of heart,brainliver, kidneys, the respiratory system, blood system, or malignant disease, or people with neck lumbar lesion, Guillain-barre syndrome, or researchers believe can affect to participate in research or in the process of research may lead to other body disease in hospital (including instability of high blood pressure) or mental illness. (3) Patients who have used drugs that are known to cause neuropathy and have had diseases that may cause neuropathy. (4) Patients with other diseases that require long-term treatment of TCM (proprietary Chinese medicine, formula granules, decoction, etc.) >= 4 weeks. (5) Patients with blindness, low vision or amblyopia. (6) Women who are pregnant, lactating or planning to become pregnant within one year. (7) Patients with known or suspected history of allergy to test drugs and excipients, or patients with allergic constitution. (8) Patients who are participating in other clinical trials. (9) Patients who are considered unfit to participate in the trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Nerve conduction velocity;Michigan Neuropathy Screening Scale;

Countries

China

Contacts

Public ContactYang Hua

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

yanghua@longhua.net+86 13916107306

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026